Home | All trials

[RDF data]
Trial NCT00000244

Resource URI: http://static.linkedct.org/resource/trials/NCT00000244
PropertyValue
linkedct:brief_title Effects of Dynorphin 1-13 on Heroin Addiction - 1
linkedct:collaborator_agency <http://static.linkedct.org/resource/collabagency/8800>
linkedct:condition <http://static.linkedct.org/resource/condition/12660>
linkedct:condition <http://static.linkedct.org/resource/condition/9249>
linkedct:criteria Inclusion Criteria: opiate addict between the ages of 18-55 Exclusion Criteria: Regular abuse of other drugs, unstable medical conditions
linkedct:description Randomized double blinded study of the effects of a single IV dose of dynorphin A 1-13 on heroin withdrawal in human opiate addicts
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 55 Years
linkedct:eligibility_minimum_age 18 Years
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date September 20, 1999
linkedct:id NCT00000244
rdfs:label Trial NCT00000244
linkedct:lastchanged_date June 23, 2005
linkedct:lead_sponsor_agency National Institute on Drug Abuse (NIDA)
linkedct:location <http://static.linkedct.org/resource/location/189935>
linkedct:nct_id NCT00000244
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title Effects of Dynorphin 1-13 on Heroin Addiction
linkedct:org_study_id NIDA-08067-1
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/45939>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000244>
linkedct:phase Phase 2
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/14203>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/20853>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/26078>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/5968>
linkedct:reference <http://static.linkedct.org/resource/reference/54759>
linkedct:secondary_id R01-08067-1
linkedct:source National Institute on Drug Abuse (NIDA)
linkedct:start_date August 1994
linkedct:study_design Treatment, Double-Blind, Placebo Control
linkedct:study_type Interventional
linkedct:summary The purpose of this study is to evaluate the effects of IV dynorphin in humans during acute heroin abstinence, in order to determine that dynorphin suppresses acute opiate withdrawal, reduces opiate craving, and is safe at doses required to produce the above effects.
rdf:type linkedct:trials
linkedct:verification_date August 1995